Chromocell Therapeutics Corp Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Chromocell Therapeutics Corp quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q3 2024.
  • Chromocell Therapeutics Corp Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.69M, a 19.2% decline year-over-year.
  • Chromocell Therapeutics Corp Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$10.1M.
  • Chromocell Therapeutics Corp annual Net Income (Loss) Attributable to Parent for 2023 was -$7.38M, a 200% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$10.1M -$1.69M -$273K -19.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$9.79M -$1.77M -$818K -85.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$8.98M -$2.56M -$1.6M -165% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$7.38M -$4.04M Oct 1, 2023 Dec 31, 2023 10-K 2024-04-16
Q3 2023 -$1.42M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$953K Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$967K Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.